Berberine Loaded Magnetic Nanoparticles for Breast Cancer Therapy on MDA-MB-231 Cells Lines

Berberine Loaded Magnetic Nanoparticles for Breast Cancer Therapy on MDA-MB-231 Cells Lines A. Venkata Satya Madhulatha Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai-600117, India https://orcid.org/0000-0002-8479-3524 C. Ronald Darwin Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai-600117, India https://orcid.org/0000-0002-2731-8196

Berberine is an alkaloid naturally-derived from Berberis aristata and a family Berberidaceae exhibits a broad spectrum of pharmacological benefits, including antiviral and anticancer properties. The recent development of nanomedicine is an art of delivering drugs to the target-site by improving their safety and efficacy. In present study, four berberine-loaded magnetic nanoparticles (BBR/MNPs) were prepared using a modified co-precipitation method with calcination. The resulting BBR/MNPs were characterized by FTIR, XRD, HRSEM, zeta potential, VSM, loading efficiency, stability and in vitro release studies. The most proven magnetic nanoparticles formulation type in dissolution was followed by in vitro anticancer studies on MDA-MB-231 cells. XRD, FTIR and TGA results proved that the formed BBR/MNPs were ordered in their structure with iron, silanol groups and berberine moieties. The HRSEM reported the average particle size of MNPs varies from 100 to 250 nm after loading with berberine also had a regular spherical shape. The value of the zeta potential was -9 mV and 15 mV at pH 6 for bare MNPs and BBR/MNPs, respectively. Loading efficiency and stability were good at BBR/MCM-41MNP. The saturated magnetization (Ms) value of Fe-MCM-41 MNP (81.76 emu/g) was obtained by VSM analysis. In vitro dissolution studies of four BBR/MNPs at a three different pH 5.5, 6.5, 7.4 including BBR/MCM-41 MNP were 86%, 84% and 82%, respectively. In vitro anticancer studies with BBR/MCM-41-MNP on treated MDA-MB-231 breast cancer cells in comparison to standard doxorubicin. The MTT assay confirmed the cytotoxic effect of BBR/MCM-41-MNP in vitro. The resulting data were statistically analyzed using one-way Anova analysis with N = 3 replicates. The IC50 values (mean standard deviation) of BBR, BBR/MCM-41 MNP and standard doxorubicin were obtained as 16.754 ± 0.651, 6.750 ± 0.048, 4.955 ± 0.042 μg/mL with significant p < 0.0001. The best result was BBR/MCM-41 MNP with an average particle size 50 nm, which showed good drug loading efficiency and size stability above 7 days. Drug release was maximal (86%) at pH 5.5. The MTT-assay confirmed that BBR/MCM-41MNP exhibited more cytotoxicity on MDA-MB-231 cells than BBR, MCM-41MNP. The IC50 of BBR/MCM-41 was closed that of standard doxorubicin. The BBR/MCM-41MNP showed the optimum drug release with potent anticancer activity along with magnetic targeting.
7 18 2022 2022 2147 2154 23880 10.14233/ajchem.2022.23880 https://asianpubs.org/index.php/ajchem/article/view/34_8_30 https://asianjournalofchemistry.co.in/user/journal/viewarticle.aspx?ArticleID=34_8_30 10.1007/s12013-014-0459-6 10.1016/j.ijgo.2015.03.015 10.1001/jama.2018.20751 10.3389/fphar.2020.632079 M.R. Ataollahi, J. Sharifi, M.R. Paknahad and A. Paknahad, J. Med. Sci. Life, 8(Suppl. 4), 6 (2015). 10.1016/j.jddst.2020.101662 S.K.S. Kushwaha, A. Rastogi, A.K. Rai and S. Singh, Int. J. Pharmtech. Res., 4, 542 (2012). 10.1038/s41572-019-0111-2 10.1186/s12951-018-0392-8 10.1063/1.4769153 T.K. Indira and P.K. Lakshmi, Int. J. Pharm. Sci. Nanotechnol., 3, 1035 (2010). 10.1155/2018/7805147 10.1016/j.colsurfb.2020.111188 10.1016/j.biopha.2018.05.067 10.3389/fmolb.2020.624494 10.3390/ma14082086 10.1007/s11164-013-1182-4 10.1021/acs.chemmater.6b00499 10.1016/j.apsusc.2018.03.223 10.1021/la051167e 10.1021/acsomega.7b01347 10.1038/s41598-020-79139-8 10.2147/IJN.S29290 10.1038/s41598-018-37796-w 10.3390/pharmaceutics13040553